



HTA Expert meeting

Current experience and developments in HTA of medtech¹ in Europe

8 May 2014 between 10:00 and 17:00 at Eucomed / EDMA offices (Rue Joseph II, 40 – 1000 Brussels)

9:30 – 10:00	Registration and Coffee
10:00 – 10:15	Welcome and Introduction
10:15 – 11:30	<p>HTA for medtech: For different medical technologies, where does HTA fit in the care pathway in Europe? (INDUSTRY PRESENTATIONS)</p> <ul style="list-style-type: none"> Pharma vs. medical technology models Examples of the role of HTA in the healthcare pathway for medtech <p>Presentation to cover examples such as:</p> <ul style="list-style-type: none"> Reimbursement pathways and reimbursement consequences Different methods and sources of information Innovation cycles and selection of technologies for HTA HTA before or after launch, periodicity of HTA Data requirements to demonstrate value
11:30 – 12:30	<p>WP7 SG3 Methodological Guideline on Medical Devices. The current guideline development process in EUnetHTA and guideline structure (EUnetHTA PRESENTATION)</p> <p>Discussion with industry</p> <ul style="list-style-type: none"> Input in the form of general comments and recommendations for special contents and methodological aspects
12:30 – 13:15	LUNCH
13:15-15:00	<p>EUnetHTA WP4 and WP5 Strand B: Discussion on challenges and current processes (EUnetHTA PRESENTATION)</p> <ul style="list-style-type: none"> Application/transferability of deliverables to national/local level HTA Identification of all manufacturers, identification and selection of other stakeholders, best ways to contact the industry Tasks of the industry (evidence submission, other relevant information) Scoping meeting(s), WP4 suggestion Confidentiality issues (evidence, confidential version of assessment)

¹ medtech = Medical Devices, In-vitro Diagnostics and Medical Imaging



	<p>WP4 and WP5 Strand B experience (INDUSTRY PRESENTATIONS)</p> <ul style="list-style-type: none">• WP4: EDMA experience• WP5 Strand B: Eucomed experience (Renal Denervation example) <p>Presentations to cover:</p> <ul style="list-style-type: none">• Limitations, including topic selection process and criteria• How to address limitations• Potential way forward
15:00 – 15:15	Coffee break
15:15 – 16:15	<p>WP7 SG4: Template development for medical devices (excluding IVDs) (EUnetHTA PRESENTATION)</p> <p>Discussion about the analysis and draft template: WP7 SG4 will send a draft report of the findings of national evidence requirements for devices and an outline for a submission template.</p> <ul style="list-style-type: none">• Evidence requirements received from reimbursement agencies• Approach to developing submission template for devices• Introduction to draft template <p>Discussion with industry:</p> <ul style="list-style-type: none">• Are our analyses complete?• Is there anything we are missing?• Are there any issues with any of the evidence requirements?
16:15 – 16:45	<p>WP7 SG1 Early Dialogues: Initial exchange of views and identification of the issues (EUnetHTA PRESENTATION)</p> <p>Discussion with industry:</p> <ul style="list-style-type: none">• Concept• Expected benefits and possible barriers and limitations• Stakeholders to be involved• Way forward
16:45 – 17:00	Wrap up, Conclusions and Next Steps